---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-277555"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:41:04.116737+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio to merge with Lenz Therapeutics; Lenz holders to own 65%

## Summary
- Graphite valued at $126.5M, LENZ at $231.6M; $60M cash dividend to pre-merger Graphite stockholders.
- LENZ stockholders will own ~65% of combined company, Graphite ~35% on fully-diluted basis.
- Concurrent PIPE investment of $53.5M (minimum $50M, up to $125M) to close alongside merger.
- Post-merger board: 7 members (5 from LENZ, 2 from Graphite); company renamed LENZ Therapeutics.

## SEC filing metadata
- accession: 0001193125-23-277555
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000119312523277555/0001193125-23-277555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000119312523277555/d896516d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-277555
- JSON: https://secwatch.observer/filing/0001193125-23-277555.json
- Plain text: https://secwatch.observer/filing/0001193125-23-277555.txt

## Key facts
- Material Agreements
  LENZ Therapeutics, Inc. entered into Agreement and Plan of Merger with Lenz Therapeutics, Inc. valued at 65% ownership post-merger for LENZ stockholders (effective 2023-11-14).
  - Action: entry
  - Agreement: merger
  - Counterparty: Lenz Therapeutics, Inc.
  - Value: 65% ownership post-merger for LENZ stockholders
  - Effective: 2023-11-14
  source text: On November 14, 2023, Graphite Bio, Inc., a Delaware corporation (“Graphite”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and between Graphite, Generate Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Graphite (“Merger Sub”), and Lenz Therapeutics, Inc., a Delaware corporation (“LENZ”), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into LENZ (the “Merger”), with LENZ continuing as a wholly owned subsidiary of Graphite and the surviving corporation of the merger.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815776/000119312523277555/0001193125-23-277555-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.